Primary Orbital Lymphoma : A Retrospective Analysis of Results of Radiation Therapy

원발성 안와 림프종의 방사선치료 성적에 관한 후향적 분석

  • Kim Sussan (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Ahn Seung Do (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Chang Hyesook (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Kim Kyoung Ju (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Lee Sang-wook (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Choi Eun Kyung (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Kim Jong Hoon (Department of Radiation Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Huh Jooryung (Department of Diagnostic Pathology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Suh Cheol Won (Department of Medical Oncology, Asan Medical Center, College of Medicine, Ul-San University) ;
  • Kim Sung Bae (Department of Medical Oncology, Asan Medical Center, College of Medicine, Ul-San University)
  • 김수산 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 안승도 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 장혜숙 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 김경주 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 이상욱 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 최은경 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 김종훈 (울산대학교 의과대학 서울아산병원 방사선종양학과) ;
  • 허주령 (울산대학교 의과대학 서울아산병원 진단병리과) ;
  • 서철원 (울산대학교 의과대학 서울아산병원 종양혈액내과) ;
  • 김성배 (울산대학교 의과대학 서울아산병원 종양혈액내과)
  • Published : 2002.06.01

Abstract

Purpose : This study evaluated the treatment outcomes, patterns of failure, and treatment related complications of primary lymphoma patients who received definitive radiation therapy. Materials and Methods : A retrospective analysis was undertaken for 31 patients with primary orbital lymphoma at the Asan Medical Center between February 1991 and April 2001. There were 18 males and 13 females with ages ranging from 3 to 73 years (median, 44 years). The involved sites were 9 conjunctivae, 12 eyelids and 10 other orbits. The histological types were 28 MALT lymphomas (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type), 1 diffuse large B-cell lymphoma, 1 anaplastic large cell lymphoma and 1 lymphoblastic lymphoma. The Ann Arbor stages were all IE $(100\%)$. Ann Arbor stage III or IV patients were excluded from this study, Bilateral orbital involvement occurred in 6 cases. Radiation therapy was given with one anterior port of high energy electrons $(6\~16\;MeV)$ for the lesions located at the anterior structures like the conjunctivae or eyelids. Lesions with a posterior extension or other orbital lesions were treated with 4 or 6 MeV photons with appropriately arranged portals. In particular, lens blocks composed of lead alloy were used in conjunctival or eyelid lesions. Twelve patients received chemotherapy. The median follow-up period was 53 months. Results : The 5-year overall, cause-specific, and disease-free survival was $91\%,\;96\%,\;and\;80\%$, respectively. The complete response rate 6 months after radiation therapy was $100\%$. Local recurrences were observed in 2 patients at 16 and 18 months after completion of radiation treatment. They were salvaged with additional radiation therapy. Two patients developed distant metastases. A MALT lymphoma patient with a lung relapse was successfully salvaged with radiotherapy, but the other lymphoblastic lymphoma patient with bone marrow relapse expired. There were no severe complications but 5 patients developed radiation-induced cataracts and 2 patients developed dry eye. Conclusion : Most primary orbital lymphomas consisted of MALT lymphomas. Radiation therapy was a successful treatment modality for orbital lymphoma without any severe complications. In cases of local relapses, radiation therapy is also a very successful salvage treatment modality.

목적 : 원발성 안와 림프종로 진단 받고 방사선치료를 받은 환자들을 대상으로 치료 반응, 재발 양상, 생존률 및 치료 부작용에 대해 알아보고자 하였다. 대상 및 방법 : 1991년 2월부터 2001년 4월까지 서울중앙병원에서 원발성 안와 림프종으로 진단 받고 방사선치료를 받은 31명의 환자를 대상으로 후향적 분석을 시행하였다. 성별분포는 남자가 18명, 여자가 13명이었다. 연령은 3세에서 73세까지 분포하였으며 중앙값은 44세였다. 원발 부위는 결막이 9명, 안검이 12명, 안와가 10명이었다. 병리학적 소견은 MALT (low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type) 림프종이 28명, diffuse large B-cell 림프종이 1명, anaplastic large cell 림프종이 1명이었으며 lymphoblastic 림프종이 1명이었다. Ann Arbor staging에 따른 병기 분포를 살펴보면 1기가 31명으로 전부를 차지하였으며 각각 비장, 신장, 골수와 맥락얼기(choroid plexus)에 병변이 있었던 환자 4명은 연구에서 제외하였다. 전체 환자 중, 양측 안와 침범이 있는 환자는 6명이었다. 방사선치료는 결막과 안검 부위는 $6\~16\;MeV$의 전자선을 이용하여 전방 1문 치료로 30 Gy/10 fractions을 조사하였고, 안와 부위는 4 MV, 6 MV의 광자선을 이용하여 쐐기를 이용한 전사방 2문 치료로 $20\~28$회에 걸쳐 총 $40\~50.4\;Gy$를 조사하였다. 특히 결막과 안검 부위는 수정체를 보호하기 위한 납차폐물이 사용되었다. 항암화학요법은 12명의 환자에서 시행되었다. 중앙 추적 관찰기간은 53개월이었다. 결과 : 전체 환자의 5년 생존율은 $90.7\%$이었으며, 2명이 질병과 무관하게 폐렴과 비소세포성 폐암으로 사망하여 질병관련(cause-specific) 5년 생존율은 $96.0\%$이었으며 5년 무병 생존율은 $80.0\%$, 5년 국소제어율은 $90.5\%$였다. 방사선치료를 받은 31명 모두가 치료 후 6개월 이내에 완전관해를 보여 완전관해율은 $100\%$였다. 이 중 국소 재발은 방사선치료 후 16개월과 18개월에 2명의 환자에서 보였고 구제 방사선치료 후 모두 완전관해를 보였다. 2명이 조사 영역 밖에서 재발하였고 lymphoblastic 림프종 환자가 방사선치료 후 18개월에 골수에서 재발하여 사망하였고 MALT 림프종 환자가 방사선치료 후 41개월에 폐에 재발하여 구제 방사선치료 후 완전관해를 보였다. 12명의 환자가 방사선치료 전에 항암화학요법을 받았으며 부분관해가 11명에서 나타났고 1명은 반응을 보이지 않았다. 방사선치료 당시 시력이 있었던 29명 중 5명에서 방사선유발 백내장이 발생하였으며 2명에서 안구건조증이 발생하였다. 결론 : 원발성 안와 림프종의 대부분이 MALT 림프종이었다. 방사선치료는 매우 좋은 치료 반응과 국소 제어율을 보였으며 높은 생존율을 보였다. 국소 재발한 경우에도 방사선치료가 구제치료의 역할을 할 수 있음을 알 수 있었으며 대부분의 환자에서 심각한 후유증을 보이지 않는 안전한 치료로 생각된다.

Keywords

References

  1. Fitzpatrick PJ, Mackoo S. Lymphoreticular tumors of the orbit. Int J Radiat Oncol Biol Phys 1984;10:333-340 https://doi.org/10.1016/0360-3016(84)90051-8
  2. The Hematolymphoreticular Study Group of the Korean Society of Pathologists. REAL classification of malignant lymphomas in the republic of Korea. Cancer 1998;83:806-812 https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V
  3. The Non-Hodgkin's Lymphoma Pathologic Classification Project. The National Cancer Institute Sponsored study of classification of non-Hodgkin's lymphomas: Summary and description at a working formulation for clinical usage. Cancer 1982:49:2112-2135 https://doi.org/10.1002/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2
  4. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361-1392
  5. Stafford SL, Kozelsky TF, Garrity JA, et al. Orbital lymphoma: radiotherapy outcome and complications. Radiother and Oncol 2001;59:139-144 https://doi.org/10.1016/S0167-8140(00)00328-5
  6. Pelloski CE, Wilder RB, Ha CS, Hess MA, Cabanillas FF, Cox JD. Clinical stage lEA-llEA orbital lymphomas: outcomes in the era of modern staging and treatment. Radiotherapy and Oncology 2001;59:145-151 https://doi.org/10.1016/S0167-8140(01)00338-3
  7. Bolek TW, Moyses HM, Marcus RB Jr, et al. Radiotherapy in the management of orbital lymphoma. Int J Radiat Oncol Biol Phys 1999;44:31-36 https://doi.org/10.1016/S0360-3016(98)00535-5
  8. Chao CKS, Lin HS, Devineni VR, Smith MS. Radiation therapy for primary orbital lymphoma. Int J Radiat Oncol Biol Phys 1995;31;929-934 https://doi.org/10.1016/0360-3016(94)00416-1
  9. Smitt MC, Donalldson SH. Radiatherapy is successful treatment for orbital lymphoma. Int J Radiat Oncol Biol Phys 1993;26:59-66 https://doi.org/10.1016/0360-3016(93)90173-S
  10. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation optic neuropathy after megavoltage external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994;30:755-763
  11. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Radiation retinopathy after external-beam irradiation: analysis of time-dose factors. Int J Radiat Oncol Biol Phys 1994;30:765-773 https://doi.org/10.1016/0360-3016(94)90347-6
  12. Parsons JT, Bova FJ, Fitzgerald CR, Mendenhall WM, Million RR. Severe dry-eye syndrome following external beam irradiation. Int J Radiat Oncol Biol Phys 1994;30:755-763
  13. Henk JM, Whitelocke RAF, Warrington AP. Radiatin dose to the lens and cataract formation. Int J Radiat Oncol Biol Phys 1993:25:815-820 https://doi.org/10.1016/0360-3016(93)90310-R
  14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481 https://doi.org/10.2307/2281868
  15. Margo CE, Mulla ZD. Malignant tumors of the orbit: Analysis of the Florida Cancer Registry. Opthalmology 1998;105:185-190 https://doi.org/10.1016/S0161-6420(98)92107-8
  16. Dunbar SF, Linggood RM, Doppke KP, Duby A, Wang CC. Conjunctival lymphoma: results and treatment with a single anterior electron field. A lens sparing approach. Int J Radiat Oncol Biol Phys 1990;19:249-257
  17. Jereb B, Lee H, Jakobiecc FA, Kutcher J. Radiotherapy of conjunctival and orbital lymphoid tumors. Int J Radiat Oncol Biol Phys 1984;10:1013-1019 https://doi.org/10.1016/0360-3016(84)90172-X
  18. Letschert JG, Gonzalez Gonzalez D, Oskam J, et al. Results of radiotherapy in patients with stage I orbital non-Hodgkin's lymphoma. Radiother Oncol 1991;22:36-44 https://doi.org/10.1016/0167-8140(91)90067-Q
  19. Esik O, Ikeda H, Mukai K, Kaneko A. A retrospective analysis of different modalities for treatment of primary orbital non-Hodgkin's lymphomas. Radiother Oncol 1996;38:13-18 https://doi.org/10.1016/0167-8140(95)01658-9
  20. Reddy EK, Bhatia P, Evans RG. Primary orbital lymphomas. Int J Radiat Oncol Biol Phys 1988;15:1239-1241 https://doi.org/10.1016/0360-3016(88)90210-6
  21. Galieni P, Polito E, Leccisotti A, et al. Localized orbital lymphoma. Haematologica 1997;82:436-439
  22. Gordon PS, Juillardd GJ, Selch MT, Parker RG, Fu YS. Orbital lymphomas and pseudolymphomas: treatment with raddiaiton therapy. Radiology 1986;159:797-799
  23. Minehan KJ, Martenson JA Jr, Garrity JA, Kurtin PJ, Banks PM, Chen MG, Earle JK. Local control and complications after radiation therapy for primary orbital lymphoma: A case for low-dose treatment. Int J Radiat Oncol Biol Phys 1991;20:791-796 https://doi.org/10.1016/0360-3016(91)90025-Y
  24. Kim YH, Fayos JV. Primary orbital lymphoma: a radiotherapeutic experience. Int J Radiat Oncol Biol Phys 1976;1:1099-1105 https://doi.org/10.1016/0360-3016(76)90082-1
  25. White WL, Ferry JA, Harris NL, et al. Ocular adnexal lymphoma. A clinicopathologic study with identification of lymphomas of mucosa associated lymphoid tissue type. Opthalmology 1995;102:1994-2006
  26. Miller TP, Dahlberg S, Cassady JR et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma, N Engl J Med 2001;339:21-26
  27. Suh HS. Radiation treatment of primary orbital lymphoid tumors-a case report-, J Korean Soc Ther Radiol 1985;3:65-68
  28. Isaacson PG, Wright DH. Malignant lymphoma of mucosal associated lymphoid tissue: A distinctive type of B cell lymphoma. Cancer 1983;52:1410-1416 https://doi.org/10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3
  29. Zinzani PL, Magagnoli M, Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: Analysis of 75 patients. J Clin Oncol 1999;17:1254-1258
  30. Le QT, Eulau SM, George TI, et al. Primary radiotherapy for localized orbital MALT lymphoma. Int J Radiat Oncol Biol Phys 2002;52(3):657-663 https://doi.org/10.1016/S0360-3016(01)02729-8